Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Amitiza

National Institute for Health and Care Excellence NICE logo

NICE backs PTC’s muscular dystrophy drug Translarna

Drug to be available on the NHS for DMD patients aged five and over

National Institute for Health and Care Excellence NICE logo

NICE approves UCB Pharma’s Cimzia

New guidance could significantly extend the patient population it could treat

- PMLiVE

Pfizer warns against price-cutting after NICE backs Bosulif

Cancer drug is the first to be re-appraised form the CDF

Bristol-Myers Squibb (BMS) building

NICE ‘no’ for Opdivo in kidney cancer

BMS oncology drug knocked-back in draft guidance

- PMLiVE

NICE finally set to back wider use of Ferring’s Firmagon

And acknowledges drug's benefits for prostate cancer that spreads to the spine

- PMLiVE

Tracking comms trends: communication and market access

From multi-disciplinary teamwork to pharma’s reputation, value and access to global briefs, our contributors tackle some of the key topics in communications today

Syneos Health®

- PMLiVE

Tracking comms trends: communication and market access

From multi-disciplinary teamwork to pharma’s reputation, value and access to global briefs, our contributors tackle some of the key topics in communications today

- PMLiVE

Tracking comms trends: Europe in the global vanguard on value

From multi-disciplinary teamwork to pharma’s reputation, value and access to global briefs, our contributors tackle some of the key topics in communications today

Celgene building

NICE rejects Celgene’s Vidaza for leukaemia

Final draft guidance cites ‘high degree of uncertainty’ over clinical efficacy

- PMLiVE

Lilly promotes Aarti Shah as chief information officer

She moves up from her role as a global brand development leader

National Institute for Health and Care Excellence NICE logo

NICE backs five new drugs after discounts agreed

Includes Novartis’ previously rejected lung cancer and melanoma therapies Zykadia and Mekinist

- PMLiVE

SMC rejects Amgen’s Repatha over lack of outcomes data

But gives GlaxoSmithKline’s asthma drug Nucala the green light

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links